Almac Group records highest ever revenue, profit and employee numbers as £200 million global expansion plans announced
June 14, 2022
Almac Group, the global contract pharmaceutical development and manufacturing organization, has today (Tuesday 14th June) reported its highest ever end-of-year results for revenue, profit, and employee numbers.
In their financial results for year ending 30 September 2021, Almac recorded a £58 million (8.6%) rise in turnover from £677 million in 2020 to £735 million in 2021. Pre-tax profits were recorded at £81 million, up from £64 million (27.1% increase) for the same period the previous year.
The report also detailed an increase in Almac’s average employee figures from 5,466 to 5,783 (5.8%) during the period of October 2020 to September 2021. Current employee numbers for the Group now sits at over 6,500 and a current global recruitment drive will increase the total number to over 8,000 over the next three years, with over 1,000 of these new roles planned for Northern Ireland.
Privately owned Almac is committed to re-investing all profits back into its business and today announces a £200 million global capital investment plan to meet increased client demand over the next three years.
Investment will take place in existing Almac locations in Northern Ireland, other sites in the UK, Europe, North America and Asia.
Almac is at the forefront of developing, manufacturing, testing and distributing essential medicines to vulnerable patients around the world. During this financial year the group was involved in the development of over 300 life-saving drugs spanning more than 20 therapeutic areas including oncology, cardiology, immunology, gene therapy and neurology. Almac was also instrumental in supporting over 200 research projects for COVID-19 vaccines and treatments.
Alan Armstrong, Almac Group CEO, said: “I am hugely proud of our achievements in the last financial year. I am incredibly grateful to every one of our employees for their part in delivering these outstanding results as we continue our vital work developing life-saving and life-enhancing medicines for our clients and patients.
“Almac is committed to re-investing all our profit back into the business to ensure we are market leading for clients and offer the best possible work environment for our people.
“For our clients, we are investing £200 million on expansion to ensure we remain the global leaders in our industry and give them, and ultimately patients across the world who receive benefit from these therapeutics, the best possible offering from Almac.”
ENDS
About Almac Group
The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialization, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organization which has grown organically over the past five decades now employing over 6,500 highly skilled personnel across 18 facilities including Europe, the USA and Asia.
The figures quoted in this announcement relate to the financial period 1 October 2020 to 30 September 2021. Employee numbers recorded in the results relates to the average figures during that financial year.
To keep up to date with latest news, follow us on Twitter and LinkedIn or visit almacgroup.com.
Share